SCHEMBL905498

SCHEMBL905498

CCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
ALDH1A1 P00352 2/20 1.00
LMNA P02545 2/20 1.00
CYP3A4 P08684 2/20 1.00
USP2 O75604 1/20 1.00
MAPK1 P28482 1/20 1.00
CASP1 P29466 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
SLCO1B3 Q9NPD5 1/20 1.00
SLCO1B1 Q9Y6L6 1/20 1.00
THRB P10828 1/20 0.51
HTT P42858 1/20 0.51
MAPT P10636 1/20 0.51
NR5A1 Q13285 1/20 0.50
PLA2G4A P47712 1/20 0.49
TP53 P04637 2/20 0.49
NPC1 O15118 1/20 0.49
GAA P10253 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5144104 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL2169353 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL5143766 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL13293980 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL5144071 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL2121215 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL18998974 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL5144176 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL21373974 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4
SCHEMBL10707120 1.00 MEN1 (1.00) MEN1KMT2AALDH1A1LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115166263-B Kit for measuring concentration of glycosylated hemoglobin and method thereof 美康生物科技股份有限公司 2025-05-02 CN claimed
CN-117106772-B Sample releasing agent for detecting virus nucleic acid 青岛金域医学检验实验室有限公司 2024-01-26 CN claimed
CN-112080585-B Novel coronavirus (SARS-CoV-2) rapid detection kit and method thereof 上海市公共卫生临床中心 2023-11-07 CN claimed
CN-114839374-A Method for accurate diagnosis of disease-targeted biomarkers in liquid biopsies 相达生物科技国际有限公司 2022-08-02 CN claimed
CN-110462400-B Method for accurate diagnosis of disease-targeted biomarkers in liquid biopsies 相达生物科技国际有限公司 2022-06-21 CN claimed
EP-3463317-A1 METHOD FOR PREPARATION OF QUICK DISSOLVING THIN FILMS CONTAINING BIOACTIVE MATERIAL WITH ENHANCED THERMAL STABILITY Aridis Pharmaceuticals, Inc. (US) 2019-04-10 EP claimed
WO-2017214187-A1 METHOD FOR PREPARATION OF QUICK DISSOLVING THIN FILMS CONTAINING BIOACTIVE MATERIAL WITH ENHANCED THERMAL STABILITY ARIDIS PHARMACEUTICALS, INC. (US) 2017-12-14 WO claimed
US-20140356396-A1 ROTAVIRUS PREPARATIONS WITH EXCESS CALCIUM IONS AND HIGH VISCOSITIES THAT ENSURE VIABILITY AT ELEVATED TEMPERATURES PULLIAM BRIAN L (US) 2014-12-04 US claimed
EP-2747777-A2 ROTAVIRUS PREPARATIONS WITH EXCESS CALCIUM IONS AND HIGH VISCOSITIES THAT ENSURE VACCINE VIABILITY AT ELEVATED TEMPERATURES Pulliam, Brian (US) 2014-07-02 EP claimed
EP-2197283-B1 FORMULATIONS FOR PRESERVATION OF ROTA VIRUS ARIDIS PHARMACEUTICALS (US) 2013-07-17 EP claimed
EP-1206189-A4 ROTAVIRUS VACCINE FORMULATIONS MERCK & CO INC (US) 2003-03-12 EP claimed
US-20020136741-A1 Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci AMERICAN CYANAMID COMPANY (US) 2002-09-26 US claimed
EP-1206189-A1 ROTAVIRUS VACCINE FORMULATIONS Merck & Co., Inc. (US) 2002-05-22 EP claimed
US-6355253-B1 BACTERICIDAL ANTIBODIES AMERICAN CYANAMID COMPANY 2002-03-12 US claimed
WO-2002011540-A1 ROTAVIRUS VACCINE FORMULATIONS MERCK & CO., INC. (US) 2002-02-14 WO claimed
WO-2001008495-A1 ROTAVIRUS VACCINE FORMULATIONS MERCK & CO., INC. (US) 2001-02-08 WO claimed
US-5521067-A Bone marrow cell adhesion molecules and process for detecting adherence between cell adhesion molecules and cells generally UNIVERSITY OF ROCHESTER (US) 1996-05-28 US claimed
WO-1995014711-A1 CELL ADHESION MOLECULES AND DETECTING ADHERENCE UNIVERSITY OF ROCHESTER (US) 1995-06-01 WO claimed
US-5357636-A Flexible protective medical gloves and methods for their use DRESDNER JR KARL P (US) 1994-10-25 US claimed
US-5335373-A Protective medical gloves and methods for their use DRESDNER JR KARL P (US) 1994-08-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020136741-A1 Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci DDOST, STT3B, STT3A MEN1 994/4885KMT2A 4498/4885ALDH1A1 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.